Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147)[Alliance]
- Citation:
- J Clin Oncol vol 38 (15_suppl) 4065
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3225
- Pharmas:
- Pfizer, Eli Lily, Sanofi
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- D. Sha H. Lee N.R. Foster Q. Shi S.R. Alberts T.C. Smyrk F.A. Sinicrope
- Networks:
- LAPS-MN026, NCRF
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- colon cancer, tumor infiltrating lymphocytes, tumor budding, risk group, prognosis